Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H31ClN6O3.2ClH |
| Molecular Weight | 523.884 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.N[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl
InChI
InChIKey=XKDCRQWZLPWLFG-LKLBIAKRSA-N
InChI=1S/C21H31ClN6O3.2ClH/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14;;/h1-3,6-7,15-17H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26);2*1H/t15-,16+,17+;;/m1../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H31ClN6O3 |
| Molecular Weight | 450.962 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PPACK is a synthetic peptide that irreversibly inhibits thrombin-mediated platelet activation by binding to the active site of thrombin with a Ki = 0.24 nM. PPACK competes with alpha-thrombin at the high-affinity site and is an antagonist of alpha-thrombin induced activation. PPACK is used as a tool for assessment of Platelet function.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Proton bridging in the interactions of thrombin with small inhibitors. | 2009-08-04 |
|
| Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. | 1988-05 |
|
| Activation of platelets by alpha-thrombin is a receptor-mediated event. D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone-thrombin, but not N alpha-tosyl-L-lysine chloromethyl ketone-thrombin, binds to the high affinity thrombin receptor. | 1986-12-05 |
Sample Use Guides
Vascular graft-bearing baboons (Papio anubis) were administered PPACK (100 nmol/kg per min) by continuous intravenous infusion. The treatment abolished platelet deposition, vascular graft occlusion, thrombus associated release of platelet-specific proteins and fibrino-peptides, platelet hemostatic plug formation, platelet aggregation and thrombin-induced blood clotting. The effects of PPACK disappeared within 15 min after the infusion was discontinued.
Route of Administration:
Intravenous
Platelet-rich plasma was incubated with 10 uM PPACK and the drug completely inhibited thrombin-induced platelet aggregation. The effect of PPACK on platelet deposition at the site of balloon injury was measured with 10 uM of the drug. Platelet deposition at the site of balloon injury was reduced by 47%.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:19:26 GMT 2025
by
admin
on
Mon Mar 31 18:19:26 GMT 2025
|
| Record UNII |
5K09050P7Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5K09050P7Z
Created by
admin on Mon Mar 31 18:19:26 GMT 2025 , Edited by admin on Mon Mar 31 18:19:26 GMT 2025
|
PRIMARY | |||
|
m9086
Created by
admin on Mon Mar 31 18:19:26 GMT 2025 , Edited by admin on Mon Mar 31 18:19:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
82188-90-7
Created by
admin on Mon Mar 31 18:19:26 GMT 2025 , Edited by admin on Mon Mar 31 18:19:26 GMT 2025
|
PRIMARY | |||
|
13042154
Created by
admin on Mon Mar 31 18:19:26 GMT 2025 , Edited by admin on Mon Mar 31 18:19:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
